Galapagos

Terratis is a French company that uses the Sterile Insect Technique (SIT) to reduce the populations of tiger mosquitoes and agricultural pests. Their mission is to diminish harmful insect populations effectively on a large scale using a scientific, innovative, ecological, and efficient approach.

Frontier Medicines Corporation is a pre-clinical stage biopharmaceutical company based in South San Francisco, California, founded in 2018. The company focuses on the discovery and development of medicines targeting cancer-causing proteins through its innovative chemoproteomics platform. This platform utilizes advanced computational methods and machine learning to identify and pharmacologically target new binding pockets on proteins, facilitating the development of small-molecule drugs. By enhancing the accessibility of these proteins, Frontier Medicines aims to provide effective treatments that can redefine the management of debilitating diseases.

CellPoint is dedicated to developing CAR-T therapies at the point of care, making these therapies more affordable and accessible to patients. CellPoint has developed a 6-day manufacturing process, powered by its proprietary xCellit real-time monitoring software system, that allows for 1 week of vein-to-vein time compared to over one month with current industrial manufacturing platforms.

Abound Bio, Inc. is a biotechnology company that focuses on the development of innovative antibody-based therapeutics targeting cancer and infectious diseases. Founded in 2019 and based in Pittsburgh, Pennsylvania, Abound Bio has established extensive human antibody libraries, enabling the rapid discovery of high-affinity binders. The company employs advanced techniques, including phage-display and yeast-display libraries, to identify and optimize antibody candidates for various applications such as IgGs, multispecific antibodies, CARs, fusion proteins, and antibody-drug conjugates. Abound Bio's research includes assessing the drugability of these candidates through measurements of aggregation, solubility, and stability, as well as producing purified antibodies for animal studies. Additionally, the company utilizes bioinformatics for sequence analysis to enhance its therapeutic development efforts.

VitalNext focuses on developing innovative products that bridge the gap between life sciences and consumer health, specifically targeting the aging population. Recognizing the global significance of healthy aging, the company creates evidence-based products designed to enhance health and well-being as individuals age. Their offerings include advanced medical nutrition aimed at improving body weight and composition in malnourished individuals, with an emphasis on increasing muscle mass. VitalNext commercializes its products through distribution and licensing agreements with specialized business partners, ensuring that their solutions reach those in need. By addressing the growing demand for effective health solutions, VitalNext aims to support people in maintaining good health over extended periods.

Cangenix provides a range of crystallographic and biophysical techniques, such as surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC), using tailored biological reagents to accelerate the understanding of compound-target interactions and utilize structural, kinetic and thermodynamic data to inform drug design.

Argenta Discovery is a privately held contract research drug discovery company.

ProStrakan is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. With more than 300 people employed by the Company, ProStrakan is headquartered in Scotland with commercial operations throughout the rest of the UK and continental Europe and a US head office. The Company's Development group is located in Galashiels, Scotland and Bedminster, New Jersey, US.

Inpharmatica specialises in the use of predictive informatics in medicinal chemistry and ADME to improve the speed and productivity of drug discovery. Founded in 1998, the company employs around 35 professionals at its UK locations in London and Cambridge. Inpharmatica’s unique proprietary technologies and skills are utilised in major discovery laboratories worldwide and use natural materials for health. Inpharmatica is unique in offering discovery technologies and services which span the full breadth of research from target through to candidate selection: the core elements are fully integrated, enabling customers to access its end-to-end technologies, or individual components and services as required.

BioFocus DPI Ltd develops gene-to-candidate drug discovery products and provides services to biotech, pharma, and patient and non-profit organizations.